VCYT
Veracyte Inc · NASDAQ
- Sector Health Technology
- Industry Medical Specialties
- Website veracyte.com
- Employees(FY) 787
- ISIN US92337F1075
Performance
+10.91%
1W
+20.93%
1M
-7.52%
3M
-7.41%
6M
-16.83%
YTD
-8.7%
1Y
Profile
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Investment Analysis Report: VCYT
Overview
In this investment analysis report, we will delve into the financial statements of Veracyte Inc. (VCYT), a company operating in the Health Technology sector within the Medical Specialties industry. We will analyze the company's financial health, earnings and revenue growth, profitability, operating margi...
Technical Analysis of VCYT 2024-05-10
Overview:
In analyzing the technical indicators for VCYT over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days.
Trend Indicators:
- Moving Averages (MA): The 5-day MA has been fluctuating around the closing prices, ...
Recent News & Updates
- 2024-05-15 17:04
Veracyte to Participate in Upcoming Investor Conferences(Business Wire)
- 2024-05-15 05:04
Veracyte to Participate in Upcoming Investor Conferences(Businesswire)
- 2024-05-13 09:55
- 2024-05-12 21:55
- 2024-05-09 06:30
Is Veracyte, Inc. (NASDAQ:VCYT) Trading At A 43% Discount?(Simply Wall St.)
- 2024-05-08 15:13
Veracyte, Inc. (NASDAQ:VCYT) Q1 2024 Earnings Call Transcript(Insider Monkey)
- 2024-05-08 08:55
- 2024-05-08 07:12
Q1 2024 Veracyte Inc Earnings Call(Thomson Reuters StreetEvents)
- 2024-05-08 03:48
- 2024-05-08 03:13
- 2024-05-07 20:55
- 2024-05-07 18:13
Veracyte: Q1 Earnings Snapshot(Associated Press Finance)
- 2024-05-07 18:00
- 2024-05-07 16:05
Veracyte Announces First Quarter 2024 Financial Results(Business Wire)
- 2024-05-07 10:55
- 2024-05-07 04:05
Veracyte Announces First Quarter 2024 Financial Results(Businesswire)
- 2024-05-06 16:05
- 2024-05-06 04:05
- 2024-04-22 17:00
- 2024-04-22 08:30
- 2024-04-22 05:00
- 2024-04-21 20:30
- 2024-04-16 08:30
- 2024-04-15 20:30
- 2024-04-02 10:33
What Makes Veracyte (VCYT) a Lucrative Investment?(Insider Monkey)
- 2024-04-01 22:33
What Makes Veracyte (VCYT) a Lucrative Investment?(Insidermonkey)
- 2024-02-27 17:55
- 2024-02-27 04:55
- 2024-02-26 15:20
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff(InvestorPlace)
- 2024-02-24 08:13
Page 1 of 6
previousnext